PDC Therapeutics is a clinical stage biotech company, developing targeted Polymer Drug Conjugates aiming to provide cancer patients with a superior therapeutic index for a “Cure with A Smile”. The company’s nanomedicine pipeline currently houses proprietary programs in various stages of preclinical and clinical development for treatment of cancer.

Cooperating with multinational pharmaceutical companies through co-development programs, PDC therapeutics is supported by an industry experienced board of scientific and supervisory experts around the world.

PDC Therapeutics is exploiting the proprietary platform technology of RS Research, an academic spin-off which has discovered a pioneering class of nanocarriers with a versatile targeting capability that results in an enhanced therapeutic index. The most advanced asset in the company’s pipeline has started its clinical trial with patients with advanced stages of solid tumors, while other assets targeting oncology indications with high unmet needs are expected to complete preclinical development by the end of 2022.

PDC Therapeutics headquarters managing global clinical trials as well as business development activities over the drug candidate pipeline developed by RS Research based on the proprietary drug delivery platform SagittaTM. This technology allows designing targeted drug candidates for different indications, which yields into development of the company’s own portfolio as well as an important co-development potential.